Sheila Sharifi,Mohammed Jafferany
Sheila Sharifi
Benzoyl Peroxide Acne Treatment Shows No Significant Association with Benzene-Related Cancers: A Multicenter Retrospective Analysis [0.03%]
苯甲酰过氧化物痤疮治疗显示与苯相关癌症无明显关联性：多中心回顾分析
Jesse Veenstra,David Ozog,Alex Stephens
Jesse Veenstra
Assessing the Diagnostic Metrics of Cutaneous Leiomyomas in Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome: an Observational Study [0.03%]
遗传性平滑肌瘤病和肾细胞癌(HLRRC)综合征中皮肤平滑肌瘤诊断指标的评定：观察研究
Lydia Ouchene,Megha Udupa,Lorena A Mija et al.
Lydia Ouchene et al.
Comment on "5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study" [0.03%]
对“用于皮肤病的5α-还原酶抑制剂不会增加女性乳腺或妇科癌症的风险：一项基于人群倾向评分匹配队列研究”的评论
Austin J Coppinger,Surya Khatri,Carlos G Wambier
Austin J Coppinger
Response to Coppinger et al., "Comment on '5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study'" [0.03%]
对Coppinger等人的“评论”的回应，“5α-还原酶抑制剂用于皮肤病并不会增加女性乳腺或妇科癌症的风险：一项基于人群倾向评分匹配的队列研究”
Li-Chi Chen,Tina Yi Jin Hsieh,Aubrey Martin et al.
Li-Chi Chen et al.
Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database [0.03%]
药物英夫利昔单抗,阿达木单抗和司库奇尤单抗在化脓性汗腺炎上市后安全性监测：来自FDA不良事件报告系统数据库的分析
Aditya Joshi,Lauren Gawey,Carissa Saadi et al.
Aditya Joshi et al.
Response to CaO et al., "Commentary: Response to 'Risk of fungal infection in patients with psoriasis receiving biologics: a retrospective single-center cohort study'" [0.03%]
对CaO等人的“评论：对‘生物制剂治疗银屑病患者真菌感染风险的回顾性单中心队列研究’的回应”的回应
Yoshihito Minami,Junichiro Hiruma,Kazuharu Harada et al.
Yoshihito Minami et al.